Alamar Biosciences awarded General Counsel John L. Brottem 29,000 shares at $0 per share on September 14, alongside 85,000 derivative securities. The transaction left Brottem with 29,000 shares and 85,000 derivative securities, each representing 100.0% of his resulting holding in the respective category.
Key Highlights
- The transaction occurred on September 14, 2026.
- John L. Brottem received 85,000 derivative securities.
- The derivative securities award represented 100.0% of his resulting holding in that category.
Alamar Biosciences, Inc. (NASDAQ: ALMR) awarded General Counsel John L. Brottem 29,000 shares at $0 per share. The award occurred on September 14, 2026, and left Brottem holding 29,000 shares.
Award Covers Shares and Derivative Securities
The transaction carried SEC transaction code A. Brottem’s resulting shares holding was 29,000, and the transaction represented about 100.0% of that resulting holding. The award also covered 85,000 derivative securities on September 14, 2026. Brottem held 85,000 derivative securities after that transaction, which represented about 100.0% of his resulting derivative securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: How many shares did Alamar Biosciences award John L. Brottem?
A: Alamar Biosciences awarded General Counsel John L. Brottem 29,000 shares at $0 per share. His resulting shares holding was 29,000.
Q: What derivative securities did Alamar Biosciences award its general counsel?
A: The award covered 85,000 derivative securities, according to the filing. Following the transaction, Brottem owned 85,000 derivative securities, representing about 100.0% of his resulting derivative securities holding.
Q: When did John L. Brottem receive the Alamar Biosciences award?
A: The transaction took place on September 14, 2026, according to the Form 4 filing. It included awards of 29,000 shares and 85,000 derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.